Ann: Bionomics' PTSD Trial Results, page-40

I am pleasantly surprised that it is holding at around $0.20 through the day. This isn't the end of BNC210 but it is a pretty big blow (understatement). I doubt that Merck will rush to the party at this time as they have no need to. They know, like everyone else here, that a capital raising will be front of mind for the company. Merck's next move will depend on their view of BNC210.

Needless to say, a cap raising is going would cause some pain. That will go through people's minds. There are more things in the cupboard but development costs will cause some deep thinking. I'm optimistic but it may take a while for any substantial recovery. It always does after a failed trial. GLTA